5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor (nicotinamide N-methyltransferase) that blocks fat storage, elevates NAD+ levels, and mimics caloric restriction effects. Research shows 7% body weight loss and muscle preservation in obese mice—without exercise/diet changes. Targets obesity, T2D, NAFLD, and aging via epigenetic/metabolic reprogramming.
Mechanism Edge: NNMT ↓ → SAM/SAH ratio shift → NAD+ ↑30–50%.
How It Works
- NNMT Inhibition: ↓Methylation of nicotinamide → NAD+ pool ↑.
- Fat Metabolism: ↓Adipogenesis, lipolysis ↑ in white fat.
- Mitochondrial Boost: SIRT1 activation → biogenesis.
- Anti-Fibrotic: ↓Collagen in liver/muscle.
Oral Bioavailability: High; half-life ~5h.
Research Evidence (Preclinical)
| Model (Dose) | Effects |
|---|---|
| Obese Mice (10mg/kg oral) | -7% BW, fat mass -40%, lean mass preserved (Front Endocrinol 2022). |
| Diet-Induced Obesity | Insulin sensitivity ↑2x, glucose tolerance normalized. |
| NAFLD | Liver TG -50%, inflammation ↓. |
| Aging | NAD+ ↑, endurance ↑ similar to CR. |
- Human Translation: Phase 1 prep; mouse-human equiv. 150–300mg/day.
Protocols (Research Contexts)
| Goal | Dose (mg/day) | Timing | Cycle |
|---|---|---|---|
| Fat Loss | 50–150 | Split TID w/ meals | 8–12 weeks |
| NAD+ Rejuvenation | 100–200 | AM/PM fasted | 12 weeks on/4 off |
| Metabolic Health | 75–100 | Daily | Ongoing |
| Stack | 100mg + NMN 500mg | Synergistic NAD | 8 weeks |
- Form: Capsules/powder; water-soluble.
Benefits Breakdown
- Weight Loss: Visceral fat target; no muscle catabolism.
- Energy/Mito: NAD+ fuels sirtuins/AMPs.
- Liver Health: Steatosis reversal.
- Performance: Endurance without AMPK crash.
- Anti-Aging: Epigenetic clock potential.
Side Effects & Safety
| Common (Mild) | Preclinical Notes | Mitigation |
|---|---|---|
| GI discomfort | None toxic | Low dose start |
| Headache | NNMT rebound? (low) | Hydrate |
- Tox: Clean LD50 >2g/kg.
- Status: Research chemical; no human trials (IND pending).
Comparisons: NNMT Inhibitors vs. NAD Boosters
| Compound | Target | Fat Loss | Oral? | Stage |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT | High | Yes | Preclinical |
| NMN/NR | NAMPT | Mod | Yes | Phase 2 |
| Resveratrol | SIRT1 | Low | Yes | Supplements |
| Metformin | AMPK | Mod | Yes | Approved |
Research Outlook
- Pipeline: Obesity trials 2025?; patents filed.
- UK: Academic/research only.
- Synergy: w/ Tirzepatide, exercise.
Disclaimer: Experimental—no human consumption.




Be the first to review “5-Amino-1MQ”